Tags : KEYNOTE-522

Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III

Tuba Khan July 30, 2019

Shots: The P-III KEYNOTE-522 study involves assessing of Keytruda + CT vs PBO + CT as neoadjuvant therapy, followed Keytruda vs PBO as adjuvant therapy in 1,174 patients in a […]readmore

Tags : KEYNOTE-522

Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : KEYNOTE-522

﻿Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III